Brisbane, Mar 19, 2009 (ABN Newswire) - ImpediMed Limited (ASX:IPD) would like to bring to the attention of all shareholders the publication: "Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study", published on the 16th March 2009 in the online edition of the Journal of Clinical Oncology. The company feels that this is a significant study, as it demonstrates both the psychosocial impact of lymphedema and the impact of the direct costs associated with lymphoedema in breast cancer patients in the first two years post operation.
